Navigation Links
New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
Date:12/13/2007

Solstice Neurosciences, Inc. Launches a Self-Guided Lesson as Prep for

In-Person Workshops

MALVERN, Pa., Dec. 13 /PRNewswire/ -- In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia (CD), Solstice Neurosciences, Inc. (Solstice) has created MYOBLOC(TM) University, an online, self-study resource that incorporates new learning technology. The course integrates multi-dimensional, life-like animation throughout the content -- with anatomy based on real patients with CD and actual injection technique demonstrations with Myobloc(R) (Botulinum Toxin Type B) Injectable Solution. The course can be accessed at http://www.myoblocuniversity.com.

"MYOBLOC(TM) University is for busy physician specialists who want to expand the scope of treatment options for their patients with cervical dystonia, and for those seeking a comprehensive review of the condition and the role of botulinum toxin type B," said Eric J. Pappert, MD, assistant professor of neurology and director of the Parkinson's Disease and Movement Disorders Program at the University of Texas Health Science Center in San Antonio, Texas and Vice President, Medical & Scientific Affairs of Solstice. Dr. Pappert led the development of MYOBLOC(TM) University.

CD is often a disabling and painful movement disorder that requires life- long management. Also known as spasmodic torticollis, it is a condition that primarily affects the cervical area of the neck. While the exact cause of CD is unknown, scientists believe the problem originates in the basal ganglia area of the brain that is instrumental in movement. The treatment goal is to lessen symptoms of spasms, pain and impaired posture, and to improve functionality.

"A broad range of treatment options are often needed to address the symptoms of cervical dystonia. The botulinum toxins are considered the primary and most effective form of treatment, which makes it critically important for physicians to be experienced with both forms of botulinum toxin available here in the U.S.," noted Dr. Pappert.
The multi-media content covered in MYOBLOC(TM) University includes:

-- Detailed overview of the clinical presentation and diagnosis of CD --

with video depictions demonstrating abnormal movements and which muscle

are involved

-- Review of currently available treatments -- oral medications, surgical

options, injections with botulinum toxin, and complementary therapies

-- Fundamentals for dosing and muscle injection techniques when using

MYOBLOC to reduce the severity of abnormal head position and neck pain

associated with CD

-- Patient case studies that illustrate the challenges and potential

solutions in managing CD patients

-- A post-test for participants to gauge their understanding of the

materials presented

Upon completing the online lesson, physicians can request in-person training with MYOBLOC, which is available through Solstice in a variety of venues. The company's overall goal is to support physicians who care for CD patients -- ranging from neurologists to physiatrists to anesthesiologists and pain management physicians.

MYOBLOC(TM) University does not offer continuing medical education credits.

About MYOBLOC

Myobloc(R) (Botulinum Toxin Type B) Injectable Solution is indicated for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

Before administering MYOBLOC, physicians should consult the full Prescribing Information.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. These adverse events are generally mild to moderate, transient, self-resolving, and more common with higher doses.

For full Prescribing Information, please visit http://www.myobloc.com.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, MYOBLOC, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit http://www.solsticeneuro.com

Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice Neurosciences, Inc.

Editor's Note: for access to current course offerings, users must register on website; users can access site regardless of medical credentials.


'/>"/>
SOURCE Solstice Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Social Network for Scientists Marks Ten Years Online
2. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
3. K-State Research Leading to Software to Help Nations Cattle Producers Identify Biosecurity Risks, Evaluate Impact of Cow-Calf Diseases Online
4. Bio Career Center Launches First Online Jobs Board for Life Science PhDs, MDs
5. New Online Help Desk Offers Safe Lifting Assistance to Healthcare Facilities
6. MIT: Leveraging learning for artificial respiration
7. MIT: Leveraging learning for artificial respiration
8. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
9. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
10. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
11. New designer toxins kill Bt-resistant insect pests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 The ... and Brayton Cryocoolers), Service (Technical Support, Product Repairs & ... - Global Forecast to 2022", published by MarketsandMarkets, the ... Billion by 2022, at a CAGR of 7.29% between ... data Tables and 94 Figures spread through 159 Pages ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... significant investments in recruiting top industry experts, and expanding its LATAM network and ... industry-leading tools for clients to manage their clinical trial projects. , The expansion ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Pittcon Organizing Committee is pleased to ... been a volunteer member of Committee since 1987. Since then, he has served in ... treasurer and was chairman for both the program and exposition committees. In his professional ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of Directors of ... John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, ... leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton ...
Breaking Biology Technology:
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/8/2016)... 8, 2016   Valencell , the leading ... it has secured $11M in Series D financing. ... new venture fund being launched by UAE-based financial ... existing investors TDF Ventures and WSJ Joshua Fund. ... its triple-digit growth and accelerate its pioneering innovation ...
Breaking Biology News(10 mins):